Evaluation of clonal hematopoiesis and mosaic loss of Y chromosome in cardiovascular risk: An analysis in prospective studies
Clonal hematopoiesis of indeterminate potential (CHIP) was initially linked to a twofold increase in atherothrombotic events. However, recent investigations have revealed a more nuanced picture, suggesting that CHIP may confer only a modest rise in myocardial infarction (MI) risk. This observed lowe...
Saved in:
| Published in | eLife Vol. 13 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
eLife Sciences Publication
12.12.2024
eLife Sciences Publications, Ltd eLife Sciences Publications Ltd |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2050-084X 2050-084X |
| DOI | 10.7554/eLife.96150 |
Cover
| Abstract | Clonal hematopoiesis of indeterminate potential (CHIP) was initially linked to a twofold increase in atherothrombotic events. However, recent investigations have revealed a more nuanced picture, suggesting that CHIP may confer only a modest rise in myocardial infarction (MI) risk. This observed lower risk might be influenced by yet unidentified factors that modulate the pathological effects of CHIP. Mosaic loss of the Y chromosome (mLOY), a common marker of clonal hematopoiesis in men, has emerged as a potential candidate for modulating cardiovascular risk associated with CHIP. In this study, we aimed to ascertain the risk linked to each somatic mutation or mLOY and explore whether mLOY could exert an influence on the cardiovascular risk associated with CHIP.
We conducted an examination for the presence of CHIP and mLOY using targeted high-throughput sequencing and digital PCR in a cohort of 446 individuals. Among them, 149 patients from the CHAth study had experienced a first MI at the time of inclusion (MI(+) subjects), while 297 individuals from the Three-City cohort had no history of cardiovascular events (CVE) at the time of inclusion (MI(-) subjects). All subjects underwent thorough cardiovascular phenotyping, including a direct assessment of atherosclerotic burden. Our investigation aimed to determine whether mLOY could modulate inflammation, atherosclerosis burden, and atherothrombotic risk associated with CHIP.
CHIP and mLOY were detected with a substantial prevalence (45.1% and 37.7%, respectively), and their occurrence was similar between MI(+) and MI(-) subjects. Notably, nearly 40% of CHIP(+) male subjects also exhibited mLOY. Interestingly, neither CHIP nor mLOY independently resulted in significant increases in plasma hs-CRP levels, atherosclerotic burden, or MI incidence. Moreover, mLOY did not amplify or diminish inflammation, atherosclerosis, or MI incidence among CHIP(+) male subjects. Conversely, in MI(-) male subjects, CHIP heightened the risk of MI over a 5 y period, particularly in those lacking mLOY.
Our study highlights the high prevalence of CHIP and mLOY in elderly individuals. Importantly, our results demonstrate that neither CHIP nor mLOY in isolation substantially contributes to inflammation, atherosclerosis, or MI incidence. Furthermore, we find that mLOY does not exert a significant influence on the modulation of inflammation, atherosclerosis burden, or atherothrombotic risk associated with CHIP. However, CHIP may accelerate the occurrence of MI, especially when unaccompanied by mLOY. These findings underscore the complexity of the interplay between CHIP, mLOY, and cardiovascular risk, suggesting that large-scale studies with thousands more patients may be necessary to elucidate subtle correlations.
This study was supported by the Fondation Cœur & Recherche (the Société Française de Cardiologie), the Fédération Française de Cardiologie, ERA-CVD (« CHEMICAL » consortium, JTC 2019) and the Fondation Université de Bordeaux. The laboratory of Hematology of the University Hospital of Bordeaux benefitted of a convention with the Nouvelle Aquitaine Region (2018-1R30113-8473520) for the acquisition of the Nextseq 550Dx sequencer used in this study.
NCT04581057. |
|---|---|
| AbstractList | Background: Clonal hematopoiesis of indeterminate potential (CHIP) was initially linked to a twofold increase in atherothrombotic events. However, recent investigations have revealed a more nuanced picture, suggesting that CHIP may confer only a modest rise in myocardial infarction (MI) risk. This observed lower risk might be influenced by yet unidentified factors that modulate the pathological effects of CHIP. Mosaic loss of the Y chromosome (mLOY), a common marker of clonal hematopoiesis in men, has emerged as a potential candidate for modulating cardiovascular risk associated with CHIP. In this study, we aimed to ascertain the risk linked to each somatic mutation or mLOY and explore whether mLOY could exert an influence on the cardiovascular risk associated with CHIP. Methods: We conducted an examination for the presence of CHIP and mLOY using targeted high-throughput sequencing and digital PCR in a cohort of 446 individuals. Among them, 149 patients from the CHAth study had experienced a first MI at the time of inclusion (MI(+) subjects), while 297 individuals from the Three-City cohort had no history of cardiovascular events (CVE) at the time of inclusion (MI(-) subjects). All subjects underwent thorough cardiovascular phenotyping, including a direct assessment of atherosclerotic burden. Our investigation aimed to determine whether mLOY could modulate inflammation, atherosclerosis burden, and atherothrombotic risk associated with CHIP. Results: CHIP and mLOY were detected with a substantial prevalence (45.1% and 37.7%, respectively), and their occurrence was similar between MI(+) and MI(-) subjects. Notably, nearly 40% of CHIP(+) male subjects also exhibited mLOY. Interestingly, neither CHIP nor mLOY independently resulted in significant increases in plasma hs-CRP levels, atherosclerotic burden, or MI incidence. Moreover, mLOY did not amplify or diminish inflammation, atherosclerosis, or MI incidence among CHIP(+) male subjects. Conversely, in MI(-) male subjects, CHIP heightened the risk of MI over a 5 y period, particularly in those lacking mLOY. Conclusions: Our study highlights the high prevalence of CHIP and mLOY in elderly individuals. Importantly, our results demonstrate that neither CHIP nor mLOY in isolation substantially contributes to inflammation, atherosclerosis, or MI incidence. Furthermore, we find that mLOY does not exert a significant influence on the modulation of inflammation, atherosclerosis burden, or atherothrombotic risk associated with CHIP. However, CHIP may accelerate the occurrence of MI, especially when unaccompanied by mLOY. These findings underscore the complexity of the interplay between CHIP, mLOY, and cardiovascular risk, suggesting that large-scale studies with thousands more patients may be necessary to elucidate subtle correlations. Funding: This study was supported by the Fondation Cœur & Recherche (the Société Française de Cardiologie), the Fédération Française de Cardiologie, ERA-CVD (« CHEMICAL » consortium, JTC 2019) and the Fondation Université de Bordeaux. The laboratory of Hematology of the University Hospital of Bordeaux benefitted of a convention with the Nouvelle Aquitaine Region (2018-1R30113-8473520) for the acquisition of the Nextseq 550Dx sequencer used in this study. Clinical trial number: NCT04581057. Clonal hematopoiesis of indeterminate potential (CHIP) was initially linked to a twofold increase in atherothrombotic events. However, recent investigations have revealed a more nuanced picture, suggesting that CHIP may confer only a modest rise in myocardial infarction (MI) risk. This observed lower risk might be influenced by yet unidentified factors that modulate the pathological effects of CHIP. Mosaic loss of the Y chromosome (mLOY), a common marker of clonal hematopoiesis in men, has emerged as a potential candidate for modulating cardiovascular risk associated with CHIP. In this study, we aimed to ascertain the risk linked to each somatic mutation or mLOY and explore whether mLOY could exert an influence on the cardiovascular risk associated with CHIP. We conducted an examination for the presence of CHIP and mLOY using targeted high-throughput sequencing and digital PCR in a cohort of 446 individuals. Among them, 149 patients from the CHAth study had experienced a first MI at the time of inclusion (MI(+) subjects), while 297 individuals from the Three-City cohort had no history of cardiovascular events (CVE) at the time of inclusion (MI(-) subjects). All subjects underwent thorough cardiovascular phenotyping, including a direct assessment of atherosclerotic burden. Our investigation aimed to determine whether mLOY could modulate inflammation, atherosclerosis burden, and atherothrombotic risk associated with CHIP. CHIP and mLOY were detected with a substantial prevalence (45.1% and 37.7%, respectively), and their occurrence was similar between MI(+) and MI(-) subjects. Notably, nearly 40% of CHIP(+) male subjects also exhibited mLOY. Interestingly, neither CHIP nor mLOY independently resulted in significant increases in plasma hs-CRP levels, atherosclerotic burden, or MI incidence. Moreover, mLOY did not amplify or diminish inflammation, atherosclerosis, or MI incidence among CHIP(+) male subjects. Conversely, in MI(-) male subjects, CHIP heightened the risk of MI over a 5 y period, particularly in those lacking mLOY. Our study highlights the high prevalence of CHIP and mLOY in elderly individuals. Importantly, our results demonstrate that neither CHIP nor mLOY in isolation substantially contributes to inflammation, atherosclerosis, or MI incidence. Furthermore, we find that mLOY does not exert a significant influence on the modulation of inflammation, atherosclerosis burden, or atherothrombotic risk associated with CHIP. However, CHIP may accelerate the occurrence of MI, especially when unaccompanied by mLOY. These findings underscore the complexity of the interplay between CHIP, mLOY, and cardiovascular risk, suggesting that large-scale studies with thousands more patients may be necessary to elucidate subtle correlations. This study was supported by the Fondation Cœur & Recherche (the Société Française de Cardiologie), the Fédération Française de Cardiologie, ERA-CVD (« CHEMICAL » consortium, JTC 2019) and the Fondation Université de Bordeaux. The laboratory of Hematology of the University Hospital of Bordeaux benefitted of a convention with the Nouvelle Aquitaine Region (2018-1R30113-8473520) for the acquisition of the Nextseq 550Dx sequencer used in this study. NCT04581057. Clonal hematopoiesis of indeterminate potential (CHIP) was initially linked to a twofold increase in atherothrombotic events. However, recent investigations have revealed a more nuanced picture, suggesting that CHIP may confer only a modest rise in myocardial infarction (MI) risk. This observed lower risk might be influenced by yet unidentified factors that modulate the pathological effects of CHIP. Mosaic loss of the Y chromosome (mLOY), a common marker of clonal hematopoiesis in men, has emerged as a potential candidate for modulating cardiovascular risk associated with CHIP. In this study, we aimed to ascertain the risk linked to each somatic mutation or mLOY and explore whether mLOY could exert an influence on the cardiovascular risk associated with CHIP.BackgroundClonal hematopoiesis of indeterminate potential (CHIP) was initially linked to a twofold increase in atherothrombotic events. However, recent investigations have revealed a more nuanced picture, suggesting that CHIP may confer only a modest rise in myocardial infarction (MI) risk. This observed lower risk might be influenced by yet unidentified factors that modulate the pathological effects of CHIP. Mosaic loss of the Y chromosome (mLOY), a common marker of clonal hematopoiesis in men, has emerged as a potential candidate for modulating cardiovascular risk associated with CHIP. In this study, we aimed to ascertain the risk linked to each somatic mutation or mLOY and explore whether mLOY could exert an influence on the cardiovascular risk associated with CHIP.We conducted an examination for the presence of CHIP and mLOY using targeted high-throughput sequencing and digital PCR in a cohort of 446 individuals. Among them, 149 patients from the CHAth study had experienced a first MI at the time of inclusion (MI(+) subjects), while 297 individuals from the Three-City cohort had no history of cardiovascular events (CVE) at the time of inclusion (MI(-) subjects). All subjects underwent thorough cardiovascular phenotyping, including a direct assessment of atherosclerotic burden. Our investigation aimed to determine whether mLOY could modulate inflammation, atherosclerosis burden, and atherothrombotic risk associated with CHIP.MethodsWe conducted an examination for the presence of CHIP and mLOY using targeted high-throughput sequencing and digital PCR in a cohort of 446 individuals. Among them, 149 patients from the CHAth study had experienced a first MI at the time of inclusion (MI(+) subjects), while 297 individuals from the Three-City cohort had no history of cardiovascular events (CVE) at the time of inclusion (MI(-) subjects). All subjects underwent thorough cardiovascular phenotyping, including a direct assessment of atherosclerotic burden. Our investigation aimed to determine whether mLOY could modulate inflammation, atherosclerosis burden, and atherothrombotic risk associated with CHIP.CHIP and mLOY were detected with a substantial prevalence (45.1% and 37.7%, respectively), and their occurrence was similar between MI(+) and MI(-) subjects. Notably, nearly 40% of CHIP(+) male subjects also exhibited mLOY. Interestingly, neither CHIP nor mLOY independently resulted in significant increases in plasma hs-CRP levels, atherosclerotic burden, or MI incidence. Moreover, mLOY did not amplify or diminish inflammation, atherosclerosis, or MI incidence among CHIP(+) male subjects. Conversely, in MI(-) male subjects, CHIP heightened the risk of MI over a 5 y period, particularly in those lacking mLOY.ResultsCHIP and mLOY were detected with a substantial prevalence (45.1% and 37.7%, respectively), and their occurrence was similar between MI(+) and MI(-) subjects. Notably, nearly 40% of CHIP(+) male subjects also exhibited mLOY. Interestingly, neither CHIP nor mLOY independently resulted in significant increases in plasma hs-CRP levels, atherosclerotic burden, or MI incidence. Moreover, mLOY did not amplify or diminish inflammation, atherosclerosis, or MI incidence among CHIP(+) male subjects. Conversely, in MI(-) male subjects, CHIP heightened the risk of MI over a 5 y period, particularly in those lacking mLOY.Our study highlights the high prevalence of CHIP and mLOY in elderly individuals. Importantly, our results demonstrate that neither CHIP nor mLOY in isolation substantially contributes to inflammation, atherosclerosis, or MI incidence. Furthermore, we find that mLOY does not exert a significant influence on the modulation of inflammation, atherosclerosis burden, or atherothrombotic risk associated with CHIP. However, CHIP may accelerate the occurrence of MI, especially when unaccompanied by mLOY. These findings underscore the complexity of the interplay between CHIP, mLOY, and cardiovascular risk, suggesting that large-scale studies with thousands more patients may be necessary to elucidate subtle correlations.ConclusionsOur study highlights the high prevalence of CHIP and mLOY in elderly individuals. Importantly, our results demonstrate that neither CHIP nor mLOY in isolation substantially contributes to inflammation, atherosclerosis, or MI incidence. Furthermore, we find that mLOY does not exert a significant influence on the modulation of inflammation, atherosclerosis burden, or atherothrombotic risk associated with CHIP. However, CHIP may accelerate the occurrence of MI, especially when unaccompanied by mLOY. These findings underscore the complexity of the interplay between CHIP, mLOY, and cardiovascular risk, suggesting that large-scale studies with thousands more patients may be necessary to elucidate subtle correlations.This study was supported by the Fondation Cœur & Recherche (the Société Française de Cardiologie), the Fédération Française de Cardiologie, ERA-CVD (« CHEMICAL » consortium, JTC 2019) and the Fondation Université de Bordeaux. The laboratory of Hematology of the University Hospital of Bordeaux benefitted of a convention with the Nouvelle Aquitaine Region (2018-1R30113-8473520) for the acquisition of the Nextseq 550Dx sequencer used in this study.FundingThis study was supported by the Fondation Cœur & Recherche (the Société Française de Cardiologie), the Fédération Française de Cardiologie, ERA-CVD (« CHEMICAL » consortium, JTC 2019) and the Fondation Université de Bordeaux. The laboratory of Hematology of the University Hospital of Bordeaux benefitted of a convention with the Nouvelle Aquitaine Region (2018-1R30113-8473520) for the acquisition of the Nextseq 550Dx sequencer used in this study.NCT04581057.Clinical trial numberNCT04581057. Clonal hematopoiesis of indeterminate potential (CHIP) was initially linked to a twofold increase in atherothrombotic events. However, recent investigations have revealed a more nuanced picture, suggesting that CHIP may confer only a modest rise in myocardial infarction (MI) risk. This observed lower risk might be influenced by yet unidentified factors that modulate the pathological effects of CHIP. Mosaic loss of the Y chromosome (mLOY), a common marker of clonal hematopoiesis in men, has emerged as a potential candidate for modulating cardiovascular risk associated with CHIP. In this study, we aimed to ascertain the risk linked to each somatic mutation or mLOY and explore whether mLOY could exert an influence on the cardiovascular risk associated with CHIP. We conducted an examination for the presence of CHIP and mLOY using targeted high-throughput sequencing and digital PCR in a cohort of 446 individuals. Among them, 149 patients from the CHAth study had experienced a first MI at the time of inclusion (MI(+) subjects), while 297 individuals from the Three-City cohort had no history of cardiovascular events (CVE) at the time of inclusion (MI(-) subjects). All subjects underwent thorough cardiovascular phenotyping, including a direct assessment of atherosclerotic burden. Our investigation aimed to determine whether mLOY could modulate inflammation, atherosclerosis burden, and atherothrombotic risk associated with CHIP. CHIP and mLOY were detected with a substantial prevalence (45.1% and 37.7%, respectively), and their occurrence was similar between MI(+) and MI(-) subjects. Notably, nearly 40% of CHIP(+) male subjects also exhibited mLOY. Interestingly, neither CHIP nor mLOY independently resulted in significant increases in plasma hs-CRP levels, atherosclerotic burden, or MI incidence. Moreover, mLOY did not amplify or diminish inflammation, atherosclerosis, or MI incidence among CHIP(+) male subjects. Conversely, in MI(-) male subjects, CHIP heightened the risk of MI over a 5 y period, particularly in those lacking mLOY. Our study highlights the high prevalence of CHIP and mLOY in elderly individuals. Importantly, our results demonstrate that neither CHIP nor mLOY in isolation substantially contributes to inflammation, atherosclerosis, or MI incidence. Furthermore, we find that mLOY does not exert a significant influence on the modulation of inflammation, atherosclerosis burden, or atherothrombotic risk associated with CHIP. However, CHIP may accelerate the occurrence of MI, especially when unaccompanied by mLOY. These findings underscore the complexity of the interplay between CHIP, mLOY, and cardiovascular risk, suggesting that large-scale studies with thousands more patients may be necessary to elucidate subtle correlations. This study was supported by the Fondation Cœur & Recherche (the Société Française de Cardiologie), the Fédération Française de Cardiologie, ERA-CVD (« CHEMICAL » consortium, JTC 2019) and the Fondation Université de Bordeaux. The laboratory of Hematology of the University Hospital of Bordeaux benefitted of a convention with the Nouvelle Aquitaine Region (2018-1R30113-8473520) for the acquisition of the Nextseq 550Dx sequencer used in this study. NCT04581057. |
| Author | Debette, Stephanie Marti, Severine Fawaz, Sami Dufossee, Melody Bidet, Audrey Broitman, Jean Couffinhal, Thierry Mansier, Olivier Tzourio, Christophe Gaufroy, Astrid Pucheu, Yann Munsch, Gaëlle Trégouët, David-Alexandre James, Chloe Soumare, Aicha |
| Author_xml | – sequence: 1 givenname: Sami surname: Fawaz fullname: Fawaz, Sami – sequence: 2 givenname: Severine surname: Marti fullname: Marti, Severine – sequence: 3 givenname: Melody surname: Dufossee fullname: Dufossee, Melody – sequence: 4 givenname: Yann surname: Pucheu fullname: Pucheu, Yann – sequence: 5 givenname: Astrid surname: Gaufroy fullname: Gaufroy, Astrid – sequence: 6 givenname: Jean surname: Broitman fullname: Broitman, Jean – sequence: 7 givenname: Audrey surname: Bidet fullname: Bidet, Audrey – sequence: 8 givenname: Aicha surname: Soumare fullname: Soumare, Aicha – sequence: 9 givenname: Gaëlle orcidid: 0000-0003-1564-9825 surname: Munsch fullname: Munsch, Gaëlle – sequence: 10 givenname: Christophe orcidid: 0000-0002-6517-2984 surname: Tzourio fullname: Tzourio, Christophe – sequence: 11 givenname: Stephanie surname: Debette fullname: Debette, Stephanie – sequence: 12 givenname: David-Alexandre orcidid: 0000-0001-9084-7800 surname: Trégouët fullname: Trégouët, David-Alexandre – sequence: 13 givenname: Chloe surname: James fullname: James, Chloe – sequence: 14 givenname: Olivier orcidid: 0000-0002-7943-8800 surname: Mansier fullname: Mansier, Olivier – sequence: 15 givenname: Thierry surname: Couffinhal fullname: Couffinhal, Thierry |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39665621$$D View this record in MEDLINE/PubMed https://hal.science/hal-04835732$$DView record in HAL |
| BookMark | eNpdkk1v1DAQhi1UREvpiTvyEYS22PFHEi5oVRVaaSUuIMHJmnXsrotjBztZqQf-O86mVC2-2Hr9zjMzmnmJjkIMBqHXlJzXQvAPZuOsOW8lFeQZOqmIICvS8B9Hj97H6CznW1JOzZuGti_QMWulFLKiJ-jP5R78BKOLAUeLtY8BPN6ZHsY4RGeyyxhCh_uYwWnsY86z7yfWuxSLGHuDXcAaUufiHrKePCScXP71Ea9DCQV_NzOKZ0gxD0aPbm9wHqeuwF-h5xZ8Nmf39yn6_vny28XVavP1y_XFerPSTJQuLMhKcsKbquUdSLaFtrFaiopx1oFuoSWcUcMEBS4qS0RFdce1EK2RteQ1O0XXC7eLcKuG5HpIdyqCUwchphsFaXTaG7W1TDYtt0S2DTdNBWAFsw0tiWittS6sTwtrmLa96bQJYwL_BPr0J7iduol7RalkNZe0EN4thN1_cVfrjZq10ikTNav2s_ftfbYUf08mj6p3WRvvIZg4ZcUoL6PkS5NvHhf2QP437GJ4vxh0mUROxj5YKFHzNqnDNqnDNrG_qou9sQ |
| Cites_doi | 10.1016/j.jacc.2022.08.740 10.1182/bloodadvances.2020004062 10.1182/blood-2017-02-769869 10.1182/blood-2015-03-631747 10.1038/s41586-020-2819-2 10.1038/ng.3821 10.1182/bloodadvances.2018024729 10.1016/j.jmoldx.2016.10.002 10.1038/s41598-018-30759-1 10.1016/j.jacc.2018.08.1038 10.1038/s41375-021-01456-2 10.1182/bloodadvances.2020001582 10.1038/s41588-022-01121-z 10.1182/bloodadvances.2019000770 10.2337/dc19-S002 10.1161/CIR.0000000000000678 10.1056/NEJMoa1701719 10.1038/s41375-022-01613-1 10.1182/bloodadvances.2020003444 10.1093/rheumatology/keac108 10.1126/science.aag1381 10.1159/000072920 10.1038/ng.2966 10.1038/s41586-022-05448-9 10.1182/blood.2022018825 10.1093/eurheartj/ehad093 10.1038/s44161-022-00206-6 10.1016/j.ebiom.2022.103964 10.1161/CIRCULATIONAHA.122.062126 10.1161/STROKEAHA.122.041416 10.1056/NEJMoa1012848 10.1177/2047487311434107 10.1161/CIRCRESAHA.120.317104 10.1016/j.jacc.2021.02.028 10.1038/s41591-021-01411-9 10.1093/eurheartj/ehw128 10.1093/eurheartj/ehz591 10.1182/blood.2022017661 10.1038/ng.3545 10.1161/CIRCGEN.123.004415 10.1001/jamacardio.2023.5095 10.1056/NEJMoa1409405 10.1056/NEJMoa1408617 10.1126/science.abn3100 |
| ContentType | Journal Article |
| Copyright | 2024, Fawaz, Marti, Dufossee et al. Attribution 2024, Fawaz, Marti, Dufossee et al 2024 Fawaz, Marti, Dufossee et al |
| Copyright_xml | – notice: 2024, Fawaz, Marti, Dufossee et al. – notice: Attribution – notice: 2024, Fawaz, Marti, Dufossee et al 2024 Fawaz, Marti, Dufossee et al |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 1XC VOOES 5PM DOA |
| DOI | 10.7554/eLife.96150 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journal Collection url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology Medicine |
| EISSN | 2050-084X |
| ExternalDocumentID | oai_doaj_org_article_bf36894f06984e82aaf53f813da17ccc PMC11637461 oai_HAL_hal_04835732v1 39665621 10_7554_eLife_96150 |
| Genre | Clinical Trial Journal Article |
| GrantInformation_xml | – fundername: ERA-CVD grantid: JTC 2019 – fundername: ; – fundername: ; grantid: JTC 2019 |
| GroupedDBID | 53G 5VS 7X7 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAKDD AAYXX ABUWG ACGFO ACGOD ACPRK ADBBV ADRAZ AENEX AFKRA AFPKN ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI CCPQU CITATION DIK DWQXO EMOBN FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IEA IHR INH INR ISR ITC KQ8 LK8 M1P M2P M48 M7P M~E NQS OK1 PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RHI RNS RPM UKHRP CGR CUY CVF ECM EIF NPM PJZUB PPXIY PQGLB 7X8 PUEGO 1XC VOOES 5PM |
| ID | FETCH-LOGICAL-c3550-fa6264048294da63ba98fc652343dac9a90431e351a452f0521cd4c559e676473 |
| IEDL.DBID | M48 |
| ISSN | 2050-084X |
| IngestDate | Wed Aug 27 01:32:57 EDT 2025 Thu Aug 21 18:29:35 EDT 2025 Fri Sep 12 12:44:41 EDT 2025 Fri Sep 05 10:31:26 EDT 2025 Tue Jul 29 01:37:51 EDT 2025 Tue Jul 01 04:08:50 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | clonal hematopoiesis medicine Atherothrombosis inflammation human |
| Language | English |
| License | 2024, Fawaz, Marti, Dufossee et al. Attribution: http://creativecommons.org/licenses/by This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3550-fa6264048294da63ba98fc652343dac9a90431e351a452f0521cd4c559e676473 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 PMCID: PMC11637461 These authors contributed equally to this work. These authors also contributed equally to this work. |
| ORCID | 0000-0003-1564-9825 0000-0002-6517-2984 0000-0002-7943-8800 0000-0001-9084-7800 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.7554/eLife.96150 |
| PMID | 39665621 |
| PQID | 3146654647 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_bf36894f06984e82aaf53f813da17ccc pubmedcentral_primary_oai_pubmedcentral_nih_gov_11637461 hal_primary_oai_HAL_hal_04835732v1 proquest_miscellaneous_3146654647 pubmed_primary_39665621 crossref_primary_10_7554_eLife_96150 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-12-12 |
| PublicationDateYYYYMMDD | 2024-12-12 |
| PublicationDate_xml | – month: 12 year: 2024 text: 2024-12-12 day: 12 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | eLife |
| PublicationTitleAlternate | Elife |
| PublicationYear | 2024 |
| Publisher | eLife Sciences Publication eLife Sciences Publications, Ltd eLife Sciences Publications Ltd |
| Publisher_xml | – name: eLife Sciences Publication – name: eLife Sciences Publications, Ltd – name: eLife Sciences Publications Ltd |
| References | Ponikowski (bib31) 2016; 37 Arends (bib4) 2023; 141 Genovese (bib14) 2014; 371 Zhou (bib43) 2016; 48 Luque Paz (bib26) 2021; 5 Wright (bib40) 2017; 49 Steensma (bib34) 2015; 126 Pascual-Figal (bib30) 2021; 77 Thygesen (bib35) 2018; 72 Sano (bib33) 2022; 377 Forsberg (bib12) 2014; 46 Zink (bib44) 2017; 130 Zekavat (bib41) 2023; 2 Fuster (bib13) 2017; 355 Vlasschaert (bib38) 2023; 141 David (bib11) 2022; 61 Li (bib23) 2017; 19 Bick (bib7) 2020; 586 Mas-Peiro (bib28) 2023; 44 Lafitte (bib22) 2013; 20 Wang (bib39) 2022; 78 Zhao (bib42) 2024; 9 Böhme (bib8) 2022; 80 Busque (bib9) 2020; 4 American Diabetes Association (bib3) 2019; 42 Jaiswal (bib18) 2017; 377 van Zeventer (bib36) 2021; 5 Ljungström (bib24) 2022; 36 Guermouche (bib15) 2020; 4 Heimlich (bib16) 2024; 17 Loftfield (bib25) 2018; 8 3C Study Group (bib1) 2003; 22 Kessler (bib20) 2022; 612 Vlasschaert (bib37) 2023; 147 Mayerhofer (bib29) 2023; 54 Jaiswal (bib17) 2014; 371 Berry (bib6) 2012; 366 Abplanalp (bib2) 2021; 128 Mas-Peiro (bib27) 2020; 41 Cook (bib10) 2019; 3 Arnett (bib5) 2019; 140 Kar (bib19) 2022; 54 Khoury (bib21) 2022; 36 Saiki (bib32) 2021; 27 |
| References_xml | – volume: 80 start-page: 1545 year: 2022 ident: bib8 article-title: Impact of clonal hematopoiesis in patients with cardiogenic shock complicating acute myocardial infarction publication-title: Journal of the American College of Cardiology doi: 10.1016/j.jacc.2022.08.740 – volume: 5 start-page: 2115 year: 2021 ident: bib36 article-title: Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged ≥80 years publication-title: Blood Advances doi: 10.1182/bloodadvances.2020004062 – volume: 130 start-page: 742 year: 2017 ident: bib44 article-title: Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly publication-title: Blood doi: 10.1182/blood-2017-02-769869 – volume: 126 start-page: 9 year: 2015 ident: bib34 article-title: Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes publication-title: Blood doi: 10.1182/blood-2015-03-631747 – volume: 586 start-page: 763 year: 2020 ident: bib7 article-title: Inherited causes of clonal haematopoiesis in 97,691 whole genomes publication-title: Nature doi: 10.1038/s41586-020-2819-2 – volume: 49 start-page: 674 year: 2017 ident: bib40 article-title: Genetic variants associated with mosaic Y chromosome loss highlight cell cycle genes and overlap with cancer susceptibility publication-title: Nature Genetics doi: 10.1038/ng.3821 – volume: 3 start-page: 2482 year: 2019 ident: bib10 article-title: Comorbid and inflammatory characteristics of genetic subtypes of clonal hematopoiesis publication-title: Blood Advances doi: 10.1182/bloodadvances.2018024729 – volume: 19 start-page: 4 year: 2017 ident: bib23 article-title: Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists publication-title: The Journal of Molecular Diagnostics doi: 10.1016/j.jmoldx.2016.10.002 – volume: 8 year: 2018 ident: bib25 article-title: Predictors of mosaic chromosome Y loss and associations with mortality in the UK Biobank publication-title: Scientific Reports doi: 10.1038/s41598-018-30759-1 – volume: 72 start-page: 2231 year: 2018 ident: bib35 article-title: Fourth Universal Definition of Myocardial Infarction (2018) publication-title: Journal of the American College of Cardiology doi: 10.1016/j.jacc.2018.08.1038 – volume: 36 start-page: 889 year: 2022 ident: bib24 article-title: Loss of Y and clonal hematopoiesis in blood-two sides of the same coin? publication-title: Leukemia doi: 10.1038/s41375-021-01456-2 – volume: 4 start-page: 3550 year: 2020 ident: bib15 article-title: High prevalence of clonal hematopoiesis in the blood and bone marrow of healthy volunteers publication-title: Blood Advances doi: 10.1182/bloodadvances.2020001582 – volume: 54 start-page: 1155 year: 2022 ident: bib19 article-title: Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis publication-title: Nature Genetics doi: 10.1038/s41588-022-01121-z – volume: 4 start-page: 2430 year: 2020 ident: bib9 article-title: High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential publication-title: Blood Advances doi: 10.1182/bloodadvances.2019000770 – volume: 42 start-page: S13 year: 2019 ident: bib3 article-title: 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019 publication-title: Diabetes Care doi: 10.2337/dc19-S002 – volume: 140 start-page: e596 year: 2019 ident: bib5 article-title: 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines publication-title: Circulation doi: 10.1161/CIR.0000000000000678 – volume: 377 start-page: 111 year: 2017 ident: bib18 article-title: Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease publication-title: The New England Journal of Medicine doi: 10.1056/NEJMoa1701719 – volume: 36 start-page: 1703 year: 2022 ident: bib21 article-title: The 5th edition of the world health organization classification of haematolymphoid tumours: Myeloid and histiocytic/dendritic neoplasms publication-title: Leukemia doi: 10.1038/s41375-022-01613-1 – volume: 5 start-page: 1442 year: 2021 ident: bib26 article-title: Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study publication-title: Blood Advances doi: 10.1182/bloodadvances.2020003444 – volume: 61 start-page: 4355 year: 2022 ident: bib11 article-title: Clonal haematopoiesis of indeterminate potential and cardiovascular events in systemic lupus erythematosus (HEMATOPLUS study) publication-title: Rheumatology doi: 10.1093/rheumatology/keac108 – volume: 355 start-page: 842 year: 2017 ident: bib13 article-title: Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice publication-title: Science doi: 10.1126/science.aag1381 – volume: 22 start-page: 316 year: 2003 ident: bib1 article-title: Vascular factors and risk of dementia: Design of the three-city study and baseline characteristics of the study population publication-title: Neuroepidemiology doi: 10.1159/000072920 – volume: 46 start-page: 624 year: 2014 ident: bib12 article-title: Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer publication-title: Nature Genetics doi: 10.1038/ng.2966 – volume: 612 start-page: 301 year: 2022 ident: bib20 article-title: Common and rare variant associations with clonal haematopoiesis phenotypes publication-title: Nature doi: 10.1038/s41586-022-05448-9 – volume: 141 start-page: 2214 year: 2023 ident: bib38 article-title: A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic data sets publication-title: Blood doi: 10.1182/blood.2022018825 – volume: 44 start-page: 1943 year: 2023 ident: bib28 article-title: Mosaic loss of Y chromosome in monocytes is associated with lower survival after transcatheter aortic valve replacement publication-title: European Heart Journal doi: 10.1093/eurheartj/ehad093 – volume: 2 start-page: 144 year: 2023 ident: bib41 article-title: TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease publication-title: Nature Cardiovascular Research doi: 10.1038/s44161-022-00206-6 – volume: 78 year: 2022 ident: bib39 article-title: Prevalence and prognostic significance of DNMT3A- and TET2- clonal haematopoiesis-driver mutations in patients presenting with ST-segment elevation myocardial infarction publication-title: EBioMedicine doi: 10.1016/j.ebiom.2022.103964 – volume: 147 start-page: 358 year: 2023 ident: bib37 article-title: Interleukin-6 receptor polymorphism attenuates clonal hematopoiesis-mediated coronary artery disease risk among 451 180 individuals in the UK Biobank publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.122.062126 – volume: 54 start-page: 938 year: 2023 ident: bib29 article-title: Prevalence and therapeutic implications of clonal hematopoiesis of indeterminate potential in young patients with stroke publication-title: Stroke doi: 10.1161/STROKEAHA.122.041416 – volume: 366 start-page: 321 year: 2012 ident: bib6 article-title: Lifetime risks of cardiovascular disease publication-title: The New England Journal of Medicine doi: 10.1056/NEJMoa1012848 – volume: 20 start-page: 283 year: 2013 ident: bib22 article-title: Predictors of cardiovascular prognosis in patients receiving optimized secondary prevention measures after acute coronary syndrome publication-title: European Journal of Preventive Cardiology doi: 10.1177/2047487311434107 – volume: 128 start-page: 216 year: 2021 ident: bib2 article-title: Clonal hematopoiesis-driver DNMT3A mutations alter immune cells in heart failure publication-title: Circulation Research doi: 10.1161/CIRCRESAHA.120.317104 – volume: 77 start-page: 1747 year: 2021 ident: bib30 article-title: Clonal hematopoiesis and risk of progression of heart failure with reduced left ventricular ejection fraction publication-title: Journal of the American College of Cardiology doi: 10.1016/j.jacc.2021.02.028 – volume: 27 start-page: 1239 year: 2021 ident: bib32 article-title: Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis publication-title: Nature Medicine doi: 10.1038/s41591-021-01411-9 – volume: 37 start-page: 2129 year: 2016 ident: bib31 article-title: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC publication-title: European Heart Journal doi: 10.1093/eurheartj/ehw128 – volume: 41 start-page: 933 year: 2020 ident: bib27 article-title: Clonal haematopoiesis in patients with degenerative aortic valve stenosis undergoing transcatheter aortic valve implantation publication-title: European Heart Journal doi: 10.1093/eurheartj/ehz591 – volume: 141 start-page: 787 year: 2023 ident: bib4 article-title: Associations of clonal hematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke publication-title: Blood doi: 10.1182/blood.2022017661 – volume: 48 start-page: 563 year: 2016 ident: bib43 article-title: Mosaic loss of chromosome Y is associated with common variation near TCL1A publication-title: Nature Genetics doi: 10.1038/ng.3545 – volume: 17 year: 2024 ident: bib16 article-title: Invasive assessment of coronary artery disease in clonal hematopoiesis of indeterminate potential publication-title: Circulation. Genomic and Precision Medicine doi: 10.1161/CIRCGEN.123.004415 – volume: 9 start-page: 233 year: 2024 ident: bib42 article-title: Somatic and germline variants and coronary heart disease in a chinese population publication-title: JAMA Cardiology doi: 10.1001/jamacardio.2023.5095 – volume: 371 start-page: 2477 year: 2014 ident: bib14 article-title: Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence publication-title: The New England Journal of Medicine doi: 10.1056/NEJMoa1409405 – volume: 371 start-page: 2488 year: 2014 ident: bib17 article-title: Age-related clonal hematopoiesis associated with adverse outcomes publication-title: The New England Journal of Medicine doi: 10.1056/NEJMoa1408617 – volume: 377 start-page: 292 year: 2022 ident: bib33 article-title: Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality publication-title: Science doi: 10.1126/science.abn3100 |
| SSID | ssj0000748819 |
| Score | 2.397857 |
| Snippet | Clonal hematopoiesis of indeterminate potential (CHIP) was initially linked to a twofold increase in atherothrombotic events. However, recent investigations... Background: Clonal hematopoiesis of indeterminate potential (CHIP) was initially linked to a twofold increase in atherothrombotic events. However, recent... |
| SourceID | doaj pubmedcentral hal proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| SubjectTerms | Adult Aged Atherothrombosis Cardiovascular Diseases - genetics Chromosomes, Human, Y - genetics clonal hematopoiesis Clonal Hematopoiesis - genetics Female Heart Disease Risk Factors High-Throughput Nucleotide Sequencing Human health and pathology Humans inflammation Life Sciences Male Medicine Middle Aged Mosaicism Myocardial Infarction - epidemiology Myocardial Infarction - genetics Prospective Studies Risk Factors |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQJSQuCGiB8CVT9Roaf8fcFtRqVZWeWqmcLK9jayO1SdW0SBz478zEu6sNHHrp1XESxzP2vFHePBNyIBLzwjSmlJ6pUmqeSo_ENVhJSgdUnKqxGvnHmZ5fyJNLdbl11BdywrI8cJ64w0USurYyVdrWMtbc-6REqploPDMhBNx9K1ttJVPjHmzAMZnNBXkGQuZhPG1T_GJR_3wSgkalfggsS-RB_g8y_-VKbgWf4xfk-Qo10lke7UvyJHavyNN8juTvXfLnaKPZTftEwxXCazrKsfY3PeTC7UB919DrfvBtoFcwKuz3k4YlsvGG_jrStqNhwk2lyDr_Smcd3JqFS7APDH1dnEmHzEHcIxfHR-ff5-XqXIUyALqoyuQhi5GwdLmVjddi4W2dgoaUVMKsBustKu5EoZiXiics7w2NDJB7RG20NOI12en6Lr4ltFJ-wZhPJmgheSPqZKIKMtkgIweoWJCD9VS7myyf4SDtQIu40SJutEhBvqEZNl1Q83psAE9wK09wD3lCQfbBiJNnzGenDttQN18ZwX-xgnxe29jBQsK_I76L_f3gBMQMrOySpiBvss03zxKQFAJQhLvriTdMXja90rXLUaybAeA1UrN3j_GJ78kzDqAK6TSMfyA7d7f38SOAorvFp9H__wKT-QzU priority: 102 providerName: Directory of Open Access Journals |
| Title | Evaluation of clonal hematopoiesis and mosaic loss of Y chromosome in cardiovascular risk: An analysis in prospective studies |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39665621 https://www.proquest.com/docview/3146654647 https://hal.science/hal-04835732 https://pubmed.ncbi.nlm.nih.gov/PMC11637461 https://doaj.org/article/bf36894f06984e82aaf53f813da17ccc |
| Volume | 13 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Nb9NAEF2VVkhcEN-4QLSgXh2y3zYXlKJUESoVQkQKJ2uz3iWWUrvEbUUP_Hdm1kmECweuzq692tnxvInfvCHkSARmhSlNKi1TqdQ8pBaJa-BJSjtUnMqwGvnTmZ7O5Me5mu-RbTPOzQa2_0ztsJ_UbL0a_vxx8x4cHvDr0EA0fOtPq-CHuY65-0H8UIQcvg3Oj69kA-c0NvngIxW1TOddrd7t-b3oFEX8IeYskSL5N_68TaP8Iy6dPCD3N4CSjrsT8JDs-foRudu1mLx5TH5NdnLetAnUrRB506jU2lw0kCZXLbV1Sc-b1laOrmBVOO4bdUsk6rXNuadVTV2PtkqRkP6OjmuY2mma4BhY-rZuk7YdPfEJmZ1Mvn6YppuWC6kD4DFKg4UER4JX81yWVouFzbPgNGSrUpTW5TZHMR4vFLNS8YCVv66UDtISr42WRjwl-3VT--eEjpRdMGaDcVpIXoosGK-cDLmTngOKTMjRdquLi05Zo4CMBC1SRIsU0SIJOUYz7IagHHa80Ky_FxvvKhZB6CyXYaTzTPqMWxuUCBmDNTPjnEvIGzBi7x7T8WmB11BSXxnBr1lCXm9tXICP4YcTW_vmqi0EhBMs-pImIc86m-_uJSBfBAwJs7Peaeg9rP9LXS2jjjcDLGykZof_txMvyD0OiAq5NIy_JPuX6yv_ChDR5WJA7pi5GZCD48nZ5y-D-L_CIHrAb9AMDls |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+clonal+hematopoiesis+and+mosaic+loss+of+Y+chromosome+in+cardiovascular+risk%3A+An+analysis+in+prospective+studies&rft.jtitle=eLife&rft.au=Fawaz%2C+Sami&rft.au=Marti%2C+Severine&rft.au=Dufossee%2C+Melody&rft.au=Pucheu%2C+Yann&rft.date=2024-12-12&rft.issn=2050-084X&rft.eissn=2050-084X&rft.volume=13&rft_id=info:doi/10.7554%2FeLife.96150&rft.externalDBID=n%2Fa&rft.externalDocID=10_7554_eLife_96150 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2050-084X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2050-084X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2050-084X&client=summon |